Literature DB >> 17906159

An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics.

Petra M Jauslin1, Hanna E Silber, Nicolas Frey, Ronald Gieschke, Ulrika S H Simonsson, Karin Jorga, Mats O Karlsson.   

Abstract

An integrated model for the glucose-insulin system describing oral glucose tolerance test data was developed, extending on a previously introduced model for intravenous glucose provocations. Model extensions comprised the description of glucose absorption by a chain of transit compartments with a mean transit time of 35 minutes, a bioavailability of 80%, and a representation of the incretin effect, expressed as a direct effect of the glucose absorption rate on insulin secretion. The ability of the model to predict the incretin effect was assessed by simulating the observed difference in insulin response following an oral glucose tolerance test compared with an isoglycemic glucose infusion mimicking an oral glucose tolerance test profile. The extension of the integrated glucose-insulin model to gain information from oral glucose tolerance test data considerably expands its range of applications because the oral glucose tolerance test is one of the most common glucose challenge experiments for assessing the efficacy of hypoglycemic agents in clinical drug development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906159     DOI: 10.1177/0091270007302168

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  31 in total

Review 1.  A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.

Authors:  Puneet Gaitonde; Parag Garhyan; Catharina Link; Jenny Y Chien; Mirjam N Trame; Stephan Schmidt
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

2.  Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic.

Authors:  Andrea Tura; Elza Muscelli; Amalia Gastaldelli; Ele Ferrannini; Andrea Mari
Journal:  Diabetologia       Date:  2014-06       Impact factor: 10.122

3.  Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.

Authors:  Cornelia B Landersdorfer; Yan-Ling He; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

4.  Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model.

Authors:  Karen B Schneck; Xin Zhang; Robert Bauer; Mats O Karlsson; Vikram P Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

5.  Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.

Authors:  Xin Zhang; Karen Schneck; Juliana Bue-Valleskey; Kwee Poo Yeo; Michael Heathman; Vikram Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

6.  Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.

Authors:  Jing Fang; Cornelia B Landersdorfer; Brenda Cirincione; William J Jusko
Journal:  AAPS J       Date:  2012-10-02       Impact factor: 4.009

Review 7.  Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes.

Authors:  Elin Nyman; Yvonne J W Rozendaal; Gabriel Helmlinger; Bengt Hamrén; Maria C Kjellsson; Peter Strålfors; Natal A W van Riel; Peter Gennemark; Gunnar Cedersund
Journal:  Interface Focus       Date:  2016-04-06       Impact factor: 3.906

8.  NEFA minimal model parameters estimated from the oral glucose tolerance test and the meal tolerance test.

Authors:  Ray C Boston; Peter J Moate
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-06-18       Impact factor: 3.619

Review 9.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment.

Authors:  Joanna Parkinson; Bengt Hamrén; Maria C Kjellsson; Stanko Skrtic
Journal:  Br J Clin Pharmacol       Date:  2016-08-16       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.